Sex-specific analysis on efficacy and safety of statins: a systematic review and quantitative meta-analysis

Back

ESC Premium Access

Sex-specific analysis on efficacy and safety of statins: a systematic review and quantitative meta-analysis

Session: Poster Session 2 - Cardiovascular risk and its modification

Topic: Lipid-Lowering Agents

Speaker: Miss M. Schreuder (Rotterdam, NL)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Miss Michelle Schreuder

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

0 follower

5 more presentations in this session

Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

Speaker: Professor P. Meikle (Melbourne, AU)

Access

Abstract

Slides

Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)

Access

Abstract

LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

Speaker: Professor G. De Ferrari (Turin, IT)

Access

Abstract

Slides

Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5

Speaker: Professor S. Bain (Swansea, GB)

Access

Abstract

Slides

Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline

Speaker: Doctor D. Fitchett (Toronto, CA)

Access

Abstract

Slides

Access the full session

Poster Session 2 - Cardiovascular risk and its modification

Speakers: Miss M. Schreuder, Professor P. Meikle, Professor S. Verma, Professor G. De Ferrari, Professor S. Bain...

Access

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources